Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 22 of 5804
-
Simple blood test could spot hidden myeloma years early
Diagnosis Not yet recruitingStudy on Early Screening of Myeloma Based on Liquid Biopsy cfDNA Fragmentomics Technology. This study aims to construct and validate a set of machine learning models for the early screening of myeloma tailored to the Chinese population, based on plasma cfDNA fragmentomics feature…
Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Diagnosis
Last updated Jul 08, 2026 00:00 UTC
-
New combo therapy aims to outsmart leukemia with less poison
Disease control Not yet recruitingThis is a prospective, open-label, single-arm, umbrella phase 2 clinical trial enrolling 32 adult patients with newly diagnosed Philadelphia chromosome-negative (Ph-) B-cell acute lymphoblastic leukemia (B-ALL). All patients receive a frontline treatment backbone consisting of lo…
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Cheap statin could slash deadly clot risk in cancer patients
Prevention Recruiting nowPatients with cancer are at high risk for life-threatening venous thromboembolism (VTE) yet rarely receive anticoagulant prophylaxis due to bleeding risks. Thus, effective prophylaxis in oncology requires a method to reduce VTE without increasing hemorrhage. The primary aim of t…
Phase: PHASE4 • Sponsor: Brigham and Women's Hospital • Aim: Prevention
Last updated Jun 27, 2026 13:06 UTC
-
Could an old transplant drug help beat brain cancer?
Disease control Not yet recruitingThis phase II/III trial tests how well adding mycophenolate mofetil, to the usual treatment with intensity-modulated radiation therapy and temozolomide works for the treatment of glioblastoma that may have spread from where it first started to nearby tissue, lymph nodes, or dista…
Phase: PHASE2, PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Stroke treatment upgrade: adding a Clot-Buster after clot removal may boost recovery
Disease control Not yet recruitingStudy Design and Duration: This domain will be conducted as part of ACT-GLOBAL platform trial and will have the nested domain name of REACT. It has a prospective, randomised, controlled, open-label, parallel group with blinded endpoint assessment (PROBE) design of up to 1,500 su…
Phase: PHASE3 • Sponsor: University of Calgary • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New stroke drug could help patients treated up to 24 hours after symptoms start
Disease control Recruiting nowMulticenter, double-blind, randomized, placebo-controlled phase III clinical trial. At the clinical sites, patients with acute ischemic stroke within 4.5-24 hours of symptom onset will be randomized to receive a single bolus injection of the recombinant non-immunogenic staphyloki…
Phase: PHASE3 • Sponsor: Supergene, LLC • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New COVID-19 vaccine candidate tested alone or as a booster with mRNA shots
⭐️ VACCINE ⭐️ Recruiting nowThe main purposes of this research study are to measure the safety (whether it causes any side effects), tolerability (if it does cause any side effects, how well your body is able to handle them), and reactions, both local at the injection site and systemic, that may occur in th…
Phase: PHASE3 • Sponsor: Invivyd, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 14:00 UTC
-
New hybrid stroke unit aims to cut lifesaving treatment time
Disease control Not yet recruitingThis study investigates whether direct transfer to an emergency stroke unit equipped with NeuAngio-CT reduces time to endovascular reperfusion in patients with acute ischemic stroke and suspected intracranial large-vessel occlusion.Those aged 18-60 years with acute ischemic strok…
Phase: PHASE3 • Sponsor: Beijing Tiantan Hospital • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New radiation rhythm may outsmart glioblastoma and save memory
Disease control Not yet recruitingThis phase III trial compares temporally-modulated pulsed radiation therapy versus standard radiation therapy in treating patients with newly diagnosed, IDH wildtype, MGMT-unmethylated glioblastoma. After completion of surgery, the standard of care for glioblastoma is radiation t…
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New pill could transform leukemia treatment, phase 3 trial begins
Disease control Recruiting nowThis Phase 3 study in adult participants with newly diagnosed low-risk APL will evaluate the efficacy, safety, and PK of an oral capsule formulation of ATO, in combination with ATRA.
Phase: PHASE3 • Sponsor: Quetzal Therapeutics • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Immunotherapy-Chemo combo before surgery shows promise for advanced ovarian cancer
Disease control Not yet recruitingThis study is a single-arm, single-center prospective clinical study that will evaluate the clinical feasibility and efficacy of immunotherapy combined with chemotherapy in the neoadjuvant treatment of ovarian cancer, in order to explore the progression-free survival of the study…
Phase: PHASE2 • Sponsor: Obstetrics & Gynecology Hospital of Fudan University • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Promising new drug combo takes on advanced lung cancer in major trial
Disease control Not yet recruitingThis study was an open-label, multi-center, randomized phase III study to evaluate the efficacy and safety of SYS6010 combined with Enlonstobart versus Immunotherapy+ Platinum-based chemotherapy as First-Line treatment for patients with PD-L1-Positive locally advanced or metastat…
Phase: PHASE3 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Eye drop breakthrough: nerve growth factor heals corneal wounds in phase 3 trial
⭐️ CURE ⭐️ Recruiting nowThis is a phase 3, randomized, multicenter, double-masked, parallel group, vehicle-controlled prospective clinical trial to evaluate the safety and efficacy of cenegermin in inducing complete epithelial healing in participants with PCED. The primary objective is the evaluation of…
Phase: PHASE3 • Sponsor: Dompé Farmaceutici S.p.A • Aim: ⭐️ CURE ⭐️
Last updated Jul 18, 2026 00:00 UTC
-
Could stem cells save Babies' brains after oxygen loss?
Disease control Not yet recruitingHypoxic-ischemic encephalopathy (HIE) is a serious condition in newborns caused by lack of oxygen and blood flow around the time of birth. Standard treatment with cooling therapy (therapeutic hypothermia) lowers the risk of death or disability, but many infants still suffer long-…
Phase: PHASE1, PHASE2 • Sponsor: Mahidol University • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Engineered immune cells take aim at stubborn leukemia
Disease control Recruiting nowThe purpose of this clinical trial is to assess the feasibility, safety and efficacy of universal CAR T-cell products targeting CLL-1, CD33, CD38 and CD123 in patients with relapsed and refractory AML. The study also aims to learn more about the function of the universal CAR T ce…
Phase: PHASE1 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Double-Targeted immune cells take aim at Hard-to-Treat blood cancers
Disease control Recruiting nowThe purpose of this study is to assess the feasibility, safety and efficacy of CD19/70 bi-specific CAR-T cell therapy in patients with CD19 and/or CD70 positive B cell malignancies. Another goal of the study is to learn more about the safety and function of the anti-CD19/70 bi-sp…
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New lung cancer cocktail aims to outperform current standard therapy
Disease control Not yet recruitingEfficacy and Safety of SYHX2011 Combined with Carboplatin and Enlonstobart versus Nab-Paclitaxel Combined with Carboplatin and Tislelizumab as First-Line Treatment for Squamous Non-Small Cell Lung Cancer
Phase: PHASE2, PHASE3 • Sponsor: Shanghai Chest Hospital • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Gene therapy shot aims to stop diabetic eye disease in its tracks
Disease control Recruiting nowDiabetic Retinopathy (DR) is a common eye condition caused by diabetes, where high blood sugar levels damage the blood vessels in the back part of the eye (called the retina). Over time, this damage can lead to vision problems and even blindness if not treated. This study will as…
Phase: PHASE2, PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Daily aspirin may slash liver cancer risk in cirrhosis patients
Prevention Not yet recruitingThis clinical trial is testing whether taking a low dose aspirin tablet (100 mg) once a day can help prevent liver cancer (hepatocellular carcinoma, HCC) in people who have cirrhosis, which is severe scarring of the liver. People with cirrhosis have a higher risk of developing HC…
Phase: PHASE3 • Sponsor: Curtin University • Aim: Prevention
Last updated Jun 27, 2026 12:08 UTC
-
Gene therapy before birth: a new hope for babies with GM1 disease
Disease control Not yet recruitingThis is a study for the administration of in utero AAV9 transfer in prenatally diagnosed Type I or Type II GM1.
Phase: PHASE1 • Sponsor: Tippi Mackenzie • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC